Skip to main content

Prevention of connexin-43 remodeling protects against Duchenne muscular dystrophy cardiomyopathy.

Citation
Himelman, E., et al. “Prevention Of Connexin-43 Remodeling Protects Against Duchenne Muscular Dystrophy Cardiomyopathy.”. The Journal Of Clinical Investigation, pp. 1713-1727.
Center University of Washington
Author Eric Himelman, Mauricio A Lillo, Julie Nouet, Patrick Gonzalez, Qingshi Zhao, Lai-Hua Xie, Hong Li, Tong Liu, Xander Ht Wehrens, Paul D Lampe, Glenn I Fishman, Natalia Shirokova, Jorge E Contreras, Diego Fraidenraich
Keywords Cardiology, Cardiovascular disease, Cell Biology, Neuromuscular disease
Abstract

Aberrant expression of the cardiac gap junction protein connexin-43 (Cx43) has been suggested as playing a role in the development of cardiac disease in the mdx mouse model of Duchenne muscular dystrophy (DMD); however, a mechanistic understanding of this association is lacking. Here, we identified a reduction of phosphorylation of Cx43 serines S325/S328/S330 in human and mouse DMD hearts. We hypothesized that hypophosphorylation of Cx43 serine-triplet triggers pathological Cx43 redistribution to the lateral sides of cardiomyocytes (remodeling). Therefore, we generated knockin mdx mice in which the Cx43 serine-triplet was replaced with either phospho-mimicking glutamic acids (mdxS3E) or nonphosphorylatable alanines (mdxS3A). The mdxS3E, but not mdxS3A, mice were resistant to Cx43 remodeling, with a corresponding reduction of Cx43 hemichannel activity. MdxS3E cardiomyocytes displayed improved intracellular Ca2+ signaling and a reduction of NADPH oxidase 2 (NOX2)/ROS production. Furthermore, mdxS3E mice were protected against inducible arrhythmias, related lethality, and the development of cardiomyopathy. Inhibition of microtubule polymerization by colchicine reduced both NOX2/ROS and oxidized CaMKII, increased S325/S328/S330 phosphorylation, and prevented Cx43 remodeling in mdx hearts. Together, these results demonstrate a mechanism of dystrophic Cx43 remodeling and suggest that targeting Cx43 may be a therapeutic strategy for preventing heart dysfunction and arrhythmias in DMD patients.

Year of Publication
2020
Journal
The Journal of clinical investigation
Volume
130
Issue
4
Number of Pages
1713-1727
Date Published
12/2020
ISSN Number
1558-8238
DOI
10.1172/JCI128190
Alternate Journal
J Clin Invest
PMID
31910160
PMCID
PMC7108916
Download citation